Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance

Tommaso, Scolaro, Marta, Manco, Mathieu, Pecqueux, Ricardo, Amorim, Rosa, Trotta, Heleen H., Van Acker, Matthias, Van Haele, Niranjan, Shirgaonkar, Stefan, Naulaerts, Jan, Daniluk, Fran, Prenen, Chiara, Varamo, Donatella, Ponti, Ginevra, Doglioni, Ana Margarida, Ferreira Campos, Juan, Fernandez Garcia, Silvia, Radenkovic, Pegah, Rouhi, Aleksandar, Beatovic, Liwei, Wang, Yu, Wang, Amalia, Tzoumpa, Asier, Antoranz, Ara, Sargsian, Mario, Di Matteo, Emanuele, Berardi, Jermaine, Goveia, Bart, Ghesquière, Tania, Roskams, Stefaan, Soenen, Thomas, Voets, Bella, Manshian, Sarah Maria, Fendt, Peter, Carmeliet, Abhishek D., Garg, Ramanuj, DasGupta, Baki, Topal, Massimiliano, Mazzone

Nature Cancer |

Many individuals with cancer are resistant to immunotherapies. Here, we identify the gene encoding the pyrimidine salvage pathway enzyme cytidine deaminase (CDA) among the top upregulated metabolic genes in several immunotherapy-resistant tumors. We show that CDA in cancer cells contributes to the uridine diphosphate (UDP) pool. Extracellular UDP hijacks immunosuppressive tumor-associated macrophages (TAMs) through its receptor P2Y6. Pharmacologic or genetic inhibition of CDA in cancer cells (or P2Y6 in TAMs) disrupts TAM-mediated immunosuppression, promoting cytotoxic T cell entry and susceptibility to anti-programmed cell death protein 1 (anti-PD-1) treatment in resistant pancreatic ductal adenocarcinoma (PDAC) and melanoma models. Conversely, CDA overexpression in CDA-depleted PDACs or anti-PD-1-responsive colorectal tumors or systemic UDP administration (re)establishes resistance. In individuals with PDAC, high CDA levels in cancer cells correlate with increased TAMs, lower cytotoxic T cells and possibly anti-PD-1 resistance. In a pan-cancer single-cell atlas, CDAhigh cancer cells match with T cell cytotoxicity dysfunction and P2RY6high TAMs. Overall, we suggest CDA and P2Y6 as potential targets for cancer immunotherapy.